Mechanistic study of pharmacodynamic regulation in tumorigenesis: Epigenetic targeting of key enzymes by active...

Epigenetic dysregulation drives tumor progression and therapeutic resistance, creating a critical need for targeted modulators. Protopanaxadiol (PPD) type ginsenosides, triterpenoid saponins from Panax ginseng, have emerged as promising natural epigenetic regulators, but their clinical translation is limited by poor bioavailability and context dependent activity. Preclinical and early clinical evidence is synthesized here to elucidate the mechanistic underpinnings and translational potential of these agents.Structurally distinct ginsenosides converge on conserved epigenetic enzyme families with tumor specific isoform selectivity: one ginsenoside modulates DNA methyltransferases (DNMTs) across ovarian, renal, and liver cancers; another selectively targets DNMTs and histone deacetylases (HDACs) in colorectal cancer (CRC); a third modulates HDACs and RNA modifiers in leukemia and breast cancer. These interventions reactivate silenced tumor suppressors, suppress epithelial mesenchymal transition (EMT), reverse metabolic reprogramming, and remodel the tumor immune microenvironment. Highly-glycosylated ginsenosides act indirectly via upstream signaling, while low-glycosylated metabolites exhibit superior bioavailability. Key mechanistic principles include family level epigenetic convergence, multi-enzyme co-regulation, and functional complementarity. Clinical translation is hindered by subtherapeutic intratumoral accumulation, lack of biomarker guided studies, and RNA modifier dependency variability. Ginsenosides represent a pharmacologically unique class of epigenetic modulators, with precision oncology potential when paired with delivery optimization and epigenetic biomarker stratification.